NEW TECHNOLOGIES FOR AFRICAN SWINE FEVER VACCINES

非洲猪瘟疫苗新技术

• 批准号: 10091291
• 金额: $ 44.9万
• 依托单位: THE PIRBRIGHT INSTITUTE
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10091291
• 关键词: NEW; TECHNOLOGIES; AFRICAN; SWINE; FEVER

VAX4ASF aims to develop a state-of-the-art platform to produce highly effective and safe vaccines against ASFV targeted for both domestic pigs and wild boars. These vaccine candidates will be designed based on an innovative and robust vaccine platform that will guarantee immune protection against the different circulating ASFV variantsin Europe, while avoiding the safety concerns arisen with the use of traditional live attenuated vaccine platforms. Vaccine candidates will effectively induce innate immune response with the adequate adaptive immunity. Moreover, the immunity induced will allow discrimination between vaccinated and infected animals, which will be monitored by complementary DIVA tests developed under the scope of the project. Given the complexity of ASFV genome and the still incomplete knowledge of the mechanisms involved in immune response to ASFV, VAX4ASF aims to further understand the molecular mechanisms of the virus and how it interacts with the host. The developed platform can be used to introduce new mutations based in this new generated knowledge which will allow to improve the efficacy and cross-protection of the vaccine prototypes. VAX4ASF will provide new virus epidemiology models and control strategies using different mathematical models, leading to a better understanding of the ASFV transmission at the wild-domestic interface. In this way, innovative policies and strategies for ASFV control and management will be generated to ensure an outstanding impact through the continuous involvement of key stakeholders as project partners (farmers, wild board managers, veterinaries, hunters, policy makers...), leading to a profound effect in animal health and worldwide economy. The project relies on a solid collaboration trajectory between leading developers of innovative Animal Health vaccines and the highest experts in ASF field at international level, including partners from Europe, USA, and Kenya for the achievement of this challenge.

VAX4ASF的目标是开发一个最先进的平台，以生产针对家猪和野猪的高效、安全的ASFV疫苗。这些候选疫苗将基于一个创新和强大的疫苗平台设计，该平台将确保对欧洲流行的不同ASFV变种的免疫保护，同时避免使用传统的减毒活疫苗平台引起的安全担忧。候选疫苗具有足够的获得性免疫，可有效诱导先天免疫反应。此外，诱导的免疫将允许对接种疫苗的动物和受感染的动物进行区分，这将通过在该项目范围内开发的补充DIVA测试进行监测。鉴于ASFV基因组的复杂性，以及对ASFV免疫应答机制的了解尚不完全，VAX4ASF旨在进一步了解病毒的分子机制以及它如何与宿主相互作用。开发的平台可以用于在新产生的知识基础上引入新的突变，这将允许提高疫苗原型的效力和交叉保护。VAX4ASF将使用不同的数学模型提供新的病毒流行病学模型和控制策略，从而更好地了解ASFV在野生-家养界面的传播。通过这种方式，将产生ASFV控制和管理的创新政策和战略，以确保通过关键利益相关者作为项目合作伙伴(农民、野生董事会管理人员、兽医、猎人、政策制定者……)的持续参与，确保产生突出的影响，从而对动物健康和世界经济产生深远影响。该项目依赖于领先的创新动物健康疫苗开发商与ASF领域国际最高水平的专家之间坚实的合作轨迹，包括来自欧洲、美国和肯尼亚的合作伙伴，以实现这一挑战。